2022年度報告
?2022
2 4 8 53 151 152 185 193 255 285 290 398 403
?2022
Margaret Han Dugan
Donald W. GlazerMichael GollerAnthony C. Hooper**Ranjeev KrishanaThomas MalleyAlessandro Riva
Corazon (Corsee) D. Sanders
Thomas MalleyAnthony C. HooperCorazon (Corsee) D. Sanders
Margaret Han Dugan
Ranjeev Krishana
Donald W. GlazerMichael GollerAnthony C. HooperAlessandro Riva
Alessandro Riva
Margaret Han Dugan
Michael GollerThomas MalleyCorazon (Corsee) D. Sanders
Anthony C. HooperMargaret Han Dugan
Ranjeev KrishanaCorazon (Corsee) D. Sanders
* 2022131
2022622
** Anthony C. Hooper202341720221231
2023416Anthony C. Hooper
?2022
1. 202221
2. 2022225
3. 2022913
4. 20222120221120
(FCG, HKFCG)Vistra Corporate Services (HK) Limited
Ernst & Young LLP
Mourant Governance Services (Cayman) Limited94 Solaris AvenueCamana BayGrand Cayman KY1-1108Cayman Islands
Mourant Ozannes
171712-1716
Mourant Governance Services (Cayman) Limited94 Solaris Avenue, Camana BayGrand Cayman KY1-1108Cayman Islands
06160
www.beigene.com
?2022
??????
?2022
????????????
?
2022
???????? ADS
??
?
2022
?2022
?(BTK)
?
PD-1?
PARP1PARP2
???
2,7005080
318,000
CMO201029
9,000
?2022
()NASDAQ: BGNE;HK: 06160; SSE:
BeiGene (Hong Kong) Co.,Limited()()
BeiGene UK, Ltd.()
()()
(
)
?2022
1. 950
??
?
(CLL)(PFS)(ORR)
BCL-2BGB-11417HPK1BGB-15025BTK(CDAC)BGB-16673OX40LAG-3TIM-3
CDACADCCAR-NKmRNA
2. 2,300
(CRO)75%
?2022
3.
??
?29354,800
800ALPINE
?BTK2022(ASH)
?
BCL-2
PD-1??
PD-1/PDL-1
?
OX40TIGITLAG-3TIM-3
4. 3,500
??BTKPD-1/PDL-1
??
?
??5.
2023
?2022
2023227
CLL/SLLR/RMCL
WMR/R MZL
R/R MCL
R/R CLL/SLL
R/R WM
WMR/R MZLR/R CLL/SLL
BTK
1LNSCLC2/3L NSCLCR/R
2/3L HCC
R/R PD-L1+ UC
MSI-HdMMR2L ESCC1L NPC1L GC/GEJC
PD-1
BLAMAA
3LBRCA
PARP
(SRE)
RANKR/R
CD19CD3T(BiTE)R/R
?2022
R/R
DNA
CastlemanIL-6
GD2?
VEGF?5
BRAF
?5
MEK
?
VEGFR
?6
mTOR
?
ALKNSCLCALK
?2022
1. 2.
3.(EU)274.
(ESCC)(ESCC)(NSCLC)5.
??
(NSCLC)6.(VEGF)7.8.ALK=BLA=BRAF=BCLL=EGFR=ESCC=GC=GEJC=
HCC=MAA=MCL=MEK=mTOR=MZL=NPC=NSCLC=R/R=SLL=UC=VEGFR=WM=
??zanubrutinibBTKBTK
BTK
?
?2022
?201911(MCL)
(WM)CD20(R/R)(MZL)MCLMZL20231
?(FDA)(CLL)(SLL)
?
(EC)WMMZLCLL
?
MCLCLLSLLR/R WM(NMPA)?CLLSLLWMsNDA202112
?R/R WMNSHANRDL
?20232
?
?2022
(NHL)(HL)2022BTK852026BTK
??tislelizumab1(PD-1)IgG4Fcγ(FcγR)
T?
(NSCLC)NSCLCNSCLC(ESCC)(NPC)PD-L1
?
(NMPA)(cHL)PD-L112(UC)(HCC)(MSI-H)(dMMR)2020
?cHLUCNRDL2021NSCLCNSCLC2/3L HCCNRDL2022NSCLCMSI-H
ESCC(NPC)NRDL
?2022
NMPA(CDE)2
?
(sBLA)(HCC)
171334220211
??
FDAESCC(BLA)
2022PD-1/PD-L13602022PD-1/L1
2025500
?2022
??pamiparib1(PARP1)PARP2
PARP-DNA
?1,300?
?20215BRCA(gBRCA)
??2021
?
?XGEVA
?denosumabRANK(RANKL)
(MM)(SRE)(GCTB)
?
?20195GCTB202011SRE20207?
202012
?
GCTB2023
?
?
BLINCYTO
?
blinatumomabCD-19CD3T
T(BiTE)60(ALL)
?202012ALL20224B20218
???KYPROLIS
?carfilzomib60
(MM)
?20217R/R MM20221
??
20233
?2022
??REVLIMID
?lenalidomide2013
(MM)20182
?
NMPAMM20176
?
201911
?
202011NMPA
??
?VIDAZA
?azacitidineDNA
?
20174-2(MDS)(CMML)20%30%(AML)20181
???
ABRAXANE
?
20203ABRAXANE
?2020325NMPA
ABRAXANE
?
202110180ABRAXANE
?ABRAXANE
?
ABRAXANE
?
EUSA Pharma??SYLVANT
?siltuximab-6(IL-6)(HIV)-8(HHV-8)Castleman(iMCD)?
202112(HIV)-8(HHV-8)Castleman(MCD)MCD(iMCD)
?2022
?
?
QARZIBA
?
βdinutuximab betaGD2NMPA
(R/R)202112
?
?
(BAT1706)???
NSCLC?
202111NMPA2021NSCLC
?
202011EMAFDABLA
2022
?2022
1495%
20172022
20231202331?
?
?
(EGFR)(ALK)
(NSCLC)EGFRALKNSCLC202212023NRDL
?
(MSI-H)(dMMR)202232023NRDL
?2022
?202242023NRDL
?
202262023NRDL
?
(EGFR)(ALK)202162021NRDL
?
(HCC)202162021NRDL
?202112021NRDL
?
PD-L112
(UC)202042020NRDL
?
2(cHL)2019122020NRDL
?2022
?
?
?
(WM)202162021NRDL
?
(MCL)202062020NRDL
?
(CLL)SLL)202062020NRDL?
?
?
BRCA(gBRCA)202152021NRDL?
?202331
?
?
?
20233
?2020NRDL
?2022
?
20172019
?
2018202020184+71120182019
(Medicare)(Medicaid)
(PBM)
myBeiGene(Co-Pay)
??
?2022
2023227
?
BTK
R/R(CLL)(SLL)+
(MCL)R/R(MZL)+/-Bcl-2
(CLL)(SLL)+CD20R/R(FL)
?PD-1
2L(ESCC)1L(HCC)2L/3L(NSCLC)(HCC)R/R(cHL)+
1L(ESCC)1L(GC)
(GEJC)1L(NPC)+ zanidatamabHER2
+
1L(GEA)+ sitravatinibRTK2L(NSCLC)+(VEGFR)*
(TIGIT)
+
1L PD-L1
(NSCLC)2L PD-L1+(ESCC)2/3L+ + 1L(NSCLC)+ +
PD-L1+
(NSCLC)1L(SCLC)
?
2022
Surzebiclimab
BGB-A425TIM-3
+ +-LBL-007LAG-3BGB-A445(OX40)+BGB-10188(PI3K)
++
B+
BBGB-15025(HPK1)+?PARP 1/2
1L(GC)+BGB-3245(BRAF)
BRAFLifirafenib(RAF)
+ mirdametinibMEK
BGB-11417(Bcl-2)
R/R(MCL)R/R(CLL)(SLL)+
B++++t(11:14)R/R
(MM)BGB-16673 (BTK
CDAC)
BBGB-23339(TYK2)**BGB-24714SMAC
^
+BGB-B167CEA x
4-1BB
+
cHL=CLL=ESCC=FL=GC=GEA=GEJC=HCC=MCL=MZL=NPC=NSCLC=R/R=SCLC=SLL=TN=
?2022
2023227
Sotorasib
(CRC)(NSCLC)tarlatamab^^(SCLC)acapatamab ^^
(NSCLC)AMG 176AMG 427^^(AML)AMG 509AMG 199^^(GC)
(GEJC)AMG 650AMG 256Sitravatinib?+ (NSCLC)Sitravatinib?+ (HCC)
(GC)(GEJC)Sitravatinib?+Zanidatamab??++
(GEA)Zanidatamab??(BTC)Zanidatamab(BC)
(GC)(GEA)ZW49HER2BGB-3245
SEA-CD70
(MDS)
(AML)DKN-01 ++
(GC)
(GEJC)LBL-007 +ABI-H3733^ BiTE
?^^ BiTE
?? XmAb
?
XencorMiratisitravatinib(NSCLC)3SAPPHIRE?? ZW251MapKureSpringWorks TherapeuticsAML=BC=BTC=CRC=GC=GEA=GEJC=HCC=MDS=NSCLC=SCLC=
?2022
SEC
?
BTK
B24BTK
?BTKBTK
?202212526
?Adium PharmaNewBridge PharmaceuticalsErkimNanolekMedison
?1010535
?2022
?
WM3ASPENNCT03053440?
CLL/SLL3SEQUOIANCT03336333CLL/SLL3
ALPINENCT03734016CLL3
MCL3(NCT04002297)3FLMZL3(NCT05100862)
2MCLWMCLL/SLLNCT03206970NCT03332173NCT03206918MZLMAGNOLIANCT03846427
?FL2ROSEWOODNCT033320172022(EHA)ROSEWOOD
MCLMZLCLL/SLLCLL/SLL
??
20231202211CLL/SLL
?
PD-1
PD-1
2113342
?2022
? NSCLC3(NCT03358875)? NSCLC3NCT03594747NCT03663205? SCLC3(NCT04005716)? NSCLC3(NCT04379635)
? HCC3(NCT03412773)? HCC2(NCT03419897)
? 3
(NCT03777657)
? (cHL)3(NCT04486391)? cHL2(NCT03209973)
?2022
? 3(NCT03967977)? 2(NCT04004221)
ESCC? ESCC3(NCT03430843)? ESCC3(NCT03783442)? ESCC3
(NCT03957590)
? MSI-H/dMMR2(NCT03736889)? 3
(NCT03924986)2022123111,000
4,00011
?2022
?
PARP1PARP2?pamiparib1(PARP1)PARP2
?DNAPARP
?20215BRCA(gBRCA)
?
(NCT03519230)2(NCT03427814)
1b(NCT03150810)
(BGB-A1217)TIGIT(BGB-A1217)TIGITIgG1
3NSCLCAdvanTIG-301(NCT04866017)AdvanTIG-302(NCT04746924)2022121,6008202112
OciperlimabAdvanTIG-202(NCT04693234)20232
?2022
Lifirafenib(BGB-283)BGB-3245RAFLifirafenibRAFLifirafenibBRAF V600EV600E BRAFKRAS/NRASlifirafenib(MAPK)BRAFBRAF
KRAS/NRASlifirafenibNSCLC
SpringWorks Therapeutics(SpringWorks)1b(NCT03905148)lifirafenibSpringWorksMEKmirdametinib(PD-0325901)
SpringWorksMapKure, LLCRAFBGB-3245MapKureBGB-3245v-RAFB(B-RAF)1(NCT04249843)Sitravatinib20181Mirati Therapeutics, Inc(Mirati)Miratisitravatinib
SitravatinibRETTAMTYRO3AxlMERVEGFR2KITMiratisitravatinib
2019sitravatinibNSCLC3SAPPHIRE2022MiratisitravatinibPD-L1
ESCC2(NCT05461794)
?2022
sitravatinibNSCLC3(NCT04921358)BGB-11417Bcl-2BGB-11417Bcl-2BGB-11417(IND)
Bcl-2
Bcl-xLBcl-2
?
2022ASHCLL(AML)(MM)1NCT04883957NCT04277637NCT04771130NCT049736052022BCL-2BGB-11417
(NCT05471843)CLL/SLL(NCT05479994)22023BGB-A445OX40BGB-A445OX40BGB-A445OX40OX40BGB-A445BGB-A445TLR9PI3KδsitravatinibBGB-A445
1(NCT04215978)20221(NCT04215978)
(NCT05661955)
?2022
ZW25(zanidatamab)HER2ZanidatamabAzymetricTMHER2Zymeworks Inc.zanidatamabzanidatamabHER2
1/2(NCT04215978)zanidatamabzanidatamabPD-1zanidatamab
HER2(BTC)2bHERIZON-BTC-01(NCT04466891)2022
20213(NCT05152147)zanidatamabHER220222LSurzebiclimab(BGB-A425)TIM-3Surzebiclimab(BGB-A425)T-3(TIM-3)IgG1
surzebiclimab1/2(NCT03744468)BGB-15025HPK1BGB-15025HPK1HPK1TCR
HPK1TBGB-15025
2021BGB-150251(NCT04649385)2023BGB-15025BGB-16673BTKCDACBGB-16733BTK(CDAC)BTKBGB-16673BTKBTKBTK
BTK(R/R)B1(NCT05006716)
?2022
BGB-23339TYK2BGB-233392(TYK2)TYK2JAKBGB-23339TYK2(JH2)(IL)-12IL-231(IFN)BGB-233391
(NCT05093270)BGB-24714SMACBGB-24714(SMAC)BGB-24714
1(NCT05381909)BGB-B167CEA4-1BBBGB-B167CEA4-1BBBGB-B167
CEA(CRC)1(NCT05494762)BGB-10188PI3KBGB-10188PI3Kδ
?1(NCT04282018)
?2022
(CMO)CMO(cGMP)cGMP
?2022
13,0001
2 x 500
??650,000
100,0002019920201224,00054,000202310,00064,000
?
95100
?2022
CMOCRO
Catalent Pharma Solutions,LLC(Catalent)Catalent
??
(API)
CMO
?2022
CROAPI
3060
20191031BeiGene Switzerland GmbH
202012???
?
?2022
12.5
LUMAKRAS? (Sotorasib)(AMG510)
AMG510
AMG 51020232(i)2023112023831AMG 510(ii)AMG 510
?2022
2019103120201215,895,001206,635,01320.5%27.8
13.45174.85
(1)(a)(b)(c)
(2)5%
(3)(a)(b)
(1)(2)
125%
20.6%
?2022
20203172020924
20.6%
20.4%(1)
(2)2020121(a)
20%(b)60(c)2023121
?
20211112021226Novartis Pharma AG
6.5
132.5
?2022
(i)(ii)PD-1(Spartalizumab)BLASpartalizumab
?2022
Ociperlimab20211219TIGITociperlimab
32023202367
7.4511.5ociperlimab
ociperlimabociperlimabociperlimab
ociperlimabociperlimab
ociperlimabociperlimabociperlimab50%
25%ociperlimab
ociperlimabociperlimab
?2022
ociperlimab120ociperlimab
(1)
(2)(Hart-Scott-RodinoAntitrust Improvements Act)
201775
2017831
??
ABRAXANE
?
2020325NMPAABRAXANE
?202110180
ABRAXANE
?
ABRAXANE
?ABRAXANE
?
?2022
?
20231304832PCT
PCTFDA
FDA
?2022
2023130
?
20342034B2034
20372034?
2033203320332033203320332033203320332033?
2031203120312031203620382031203120362038
(1)
?2022
BMS2023130
?
2023202320232023?
2023130
?
2022
?
2029?
2025??
NMPA
?
?2022
FDA
FDA14
BeiGeneBeiGene
?2022
?
CD20BBTKBTK
?
2013FDAMCL90BTKCALQUENCE
?(acalabrutinib)2017FDAMCL201911CLL/SLL2023127FDAJAYPIRCA?pirtobrutinibBTK
BTKR/R MCL
?2017
?2020
??
–FDAPD-1PD-L1
?BMS
???BAVENCIO
?
LIBTAYO
?
JEMPERLI
??
PD-1PD-L1202321PD-1
????????H
?
PD-L1????
AkesoPD-1xCTLA-4
? (cadonilimab)40PD-1PD-L1
?2022
?
PARP20188?
201912NMPA?
202012
TIGITAgenusArcusCompugeniTeos TherapeuticsMereo BiopharmaSeagen
TIGIT3
?2022
?2022
.
2017
201910201920202021
???
?2022
.
?2022
.
MedicareMedicaid
(Centers for Medicare and Medicaid Services, CMS)
CMS
?2022
FDA
????
?2022
?
?2022
??????????
?2022
????????
?2022
???
?2022
(IRB)
CROGMP
IRB
?2022
NMPA
?2022
2020325NMPAABRAXANE
?
ABRAXANEABRAXANE
?
(Federal Anti-Kickback Statute)(Federal False Claims Act)
20034(April 2003 Office of Inspector General Compliance Program Guidance for PharmaceuticalManufacturers)
?2022
MedicareMedicaid
?2022
340BFSS
Tricare
CMS
340B340B
340B340BDFSSTricare
FCA
?2022
340B340B340B340B
FDA
FDAFDA
FDA
(NMPA)(EMA)
?2022
FDANMPAEMA
???????????
?2022
20226
?
20231
?
20227FDA?
(ESCC)FDAFDAFDA
FDA20203FDA
FDAFDAFDA
?2022
FDA
FDAFDAIND(i)GCP(ii)FDAFDA(i)(ii)(iii)FDAFDAFDAFDA
FDAFDA
?2022
FDANMPAEMA
2020325NMPAABRAXANE
?
ABRAXANE
?
ABRAXANE
?
FDANMPAEMA
?
FDANMPAEMA
?2022
FDANMPAEMA
??? FDANMPAEMA??FDANMPAEMAFDANMPAEMAFDANMPAEMA
?2022
???????
2022FDORAFDAFDORAFDA
FDAFDA
?2022
FDA
20201ABRAXANE
?ABRAXANE
?
2020325NMPAABRAXANE
?
ABRAXANE
?
20208
??
?2022
Hatch-Waxman
FDAFDA
2020NMPA
(NIPA)
AE
?2022
SAE
SECAESAEIRAE
????? (REMS)
?
??
?2022
202282022(Inflation Reduction Act of 2022)
D2,000DBD
?2022
(Affordable Care Act)
201720212022123171
12.5
?2022
2022202120201231151313202220212020
2015162017
201792019
?2022
?2022
20221231395506.653
20221231
?2022
?2022
(USPTO)
?2022
?2022
FDAANDA
ANDAANDAFTCANDAANDAFTC
?2022
?2022
20232024
?
2027PARP20272031TIGITPD-1
ociperlimab2034
?2022
FDA
?2022
?2022
???
Catalent Pharma Solutions, LLCCatalent
?
?2022
?
??
? FDA
????
?2022
2020325NMPAABRAXANE
?
ABRAXANE
?ABRAXANE
?
?
2022
20178
??
ABRAXANE
?2020325NMPAABRAXANE
?
ABRAXANE
?ABRAXANE
?2019
???20211(Novartis Pharma AG)
PD-1
?
202112
TIGITociperlimab
201720196202110ABRAXANE
?
?2022
(i)(ii)(iii)
??
????
?2022
???
?2022
GMP
2020325NMPAABRAXANE
?
ABRAXANE
?ABRAXANE
?
?2022
???HGRAC20202022KRAS G12CLUMAKRAS (sotorasib)(AMG510)
HGRACAMG 51020232(i)2023112023831
AMG 510(ii)AMG 510HGRAC
?2022
*20228,0009,00015%
????
?2022
?2022
2019
?2022
202277202291
HGRACNMPA
2021312021415
?2022
FDANMPAEMAFDANMPAEMA
? FDANMPAEMA?? FDANMPAEMA
?2022
?2022
1934
2002
????
?2022
????
20201206,635,013
20.5%
(i)(ii)(iii)20226202281
?2022
20202
?2022
?
2022
?2022
?2022
PIPL
?2022
PIPL
PIPL
20229
?2022
202291
11101
20233
?2022
2022215
?2022
PIPLPIPL
PIPL5,0005%PIPL
PIPL
?2022
2019
?2022
FDA
FDAFDA
?2022
?2022
?2022
2017LIBOR2021LIBOR
LIBOR2020113020211231LIBOR2023630LIBOR
LIBORLIBORLIBORLIBOR
?2022
OECD/G20
(BEPS)2020201911
2.02019430
201911201971201911
?2022
?2022
20217
20217VIE20232175
2023331
ADS
?2022
2023224
2023331
?2022
10-K
20142021
Holding Foreign Companies Accountable ActHFCAA2020122021
202233010-K
202238202212Accelerating Holding Foreign Companies Accountable ActAHFCAA
?2022
Ernst &Young LLP20221231
20228262022911202212
Ernst & Young LLP
Ernst & Young LLP202110
?2022
201220142015
20142021
Ernst &Young LLP20221231
?2022
1979
20201
2021118
?2022
20203
???
?2022
202321752023331
?2022
?2022
2020122021118
?2022
10%50%
2022123135
2016
?2022
10%
25%5%
BeiGene (Hong Kong) Co., Ltd.20101122
(i)(ii)(iii)(iv)
?2022
25%
10%20%
10%20%
?2022
25%
10%
?
2022
?2022
?2022
?2022
ADSBGNE06160688235ADS
20232141,356,140,1800.0001863,876,312
66,452,02413115,055,260
?2022
2020511S-3300,197,77217,297,026224,861,338
?2022
?2022
?
2022
????
?2022
\
?
2022
202112151933
?2022
?2022
2018
0.2%0.1%
?2022
?2022
202321455%
(1)75%(2)50%
(PFIC)20221231
(Internal Revenue Service)
?2022
F
50%50%10%10%1986(Internal Revenue Code of 1986)
?2022
123120182019202020212022
130,885222,596308,874633,9871,254,612
67,335205,616–542,296161,309198,220428,212308,8741,176,2831,415,921169,515357,022238,2171,011,3771,129,446689,829943,5861,618,1941,438,5881,961,037674,033950,5781,628,5911,457,8162,003,815673,769948,6281,624,9741,457,8162,003,815(%)86%83%77%86%80%(%)-340%-222%-527%-124%-142%
1231
20182019202020212022
740,713620,7751,390,0054,382,8873,875,0371,068,509364,7283,268,7252,241,962665,2511,697,390862,3843,885,4916,014,3253,738,5502,249,6841,612,2895,534,7958,535,5256,379,290496,037633,9341,731,5142,402,9621,995,935
14,44516,150–––1,753,647978,3553,803,2816,132,5634,383,355
(1) 10-K
?2022
?(BTK)
?
PD-1?
PARP1PARP2
???
2,7005080
318,000
CMO
201029
9,000
?2022
2023224NMPA
?
PD-L1(G/GEJ)2023119FDA
?
(CLL)(SLL)2023119(MHRA)
?
CLLCD20(MZL)2023118PD-1
?
2022
?
RANKL
?
2023
20221230NMPA(CDE)
?(HCC)(sBLA)20221117(EC)
?
(TN)(R/R)CLL20221110
?
(WM)CD20(R/R)MZL
?2022
1. 950
??
?
(CLL)(PFS)(ORR)
BCL-2BGB-11417HPK1BGB-15025BTK(CDAC)BGB-16673OX40LAG-3TIM-3
CDACADCCAR-NKmRNA
2. 2,300
(CRO)75%
?2022
3.
??
?29354,800
800ALPINE
?
BTK2022(ASH)
?
BCL-2
PD-1
??
PD-1/PDL-1?
OX40TIGITLAG-3TIM-3
4. 3,500
??BTKPD-1/PDL-1
??
?
??5.
2023
?2022
20211(1)
(2)
?2022
202112
TIGIT
?????
(1)(2)
(3)
?2022
? (CROs)CMOs???????
?2022
?
?
BTK?
?
PD-1? TIGIT?
?
PARP1PARP2? BGB-150251(HPK1)? BGB-11417Bcl-2? BGB-A445OX40? BGB-16673BTKCDAC? BGB-A425TIM-3? BGB-10188PI3Kδ? BGB-233392(TYK2)? LBL-007LAG-3
?? Mirati Therapeutics, Inc.Mirati? ZW25(Zanidatamab)ZW49Zymeworks Inc.ZymeworksHER2?
?
(BAT1706)
?
?2022
???????????
?2022
?2022
202112
?2022
202220211231
202220211231
123120222021%
1,254,612633,987620,62597.9% 161,309542,296(380,987)(70.3)%
1,415,9211,176,283239,63820.4% 286,475164,906121,56973.7% 1,640,5081,459,239181,26912.4% 1,277,852990,123287,72929.1% 75175010.1%
3,205,5862,615,018590,56822.6%(1,789,665)(1,438,735)(350,930)24.4% 52,480(15,757)68,237(433.1)% (223,852)15,904(239,756)(1,507.5)%
(1,961,037)(1,438,588)(522,449)36.3%
42,77819,22823,550122.5%(2,003,815)(1,457,816)(545,999)37.5%
?2022
2021123112202212312.396
6.50
202220211231
123120222021%1,254,612633,987620,62597.9%
–484,646(484,646)(100.0)%46,82253,671(6,849)(12.8)%104,9943,979101,0152,538.7%9,493–9,493161,309542,296(380,987)(70.3)%1,415,9211,176,283239,63820.4%
123120222021%
?
564,651217,987346,664159.0%?
422,885255,119167,76665.8%
?
79,04970,0658,98412.8%
?
63,39845,95617,44238.0%
?
38,1241,35336,7712,717.7%
?
36,10712,51523,592188.5%
?
15,21319,591(4,378)(22.3)%
?
13,696–13,696
?
5,4603,6611,79949.1%16,0297,7408,289107.1%1,254,612633,987620,62597.9%
?2022
20221231136.34
???
20218
??
2022(NRDL)
??
NRDL20221231
?
5.647159.0%202212
?
3.8971.157237.0%MCLWMMZL20221231?
1.50348.6%CLLSLL20221231
?
4.229
65.8%20221231
??2021320221NRDL
?
20214,560
202112315,750
???
202131NRDL
???
202211NRDLNRDL
20211231
????
NRDLNRDL202212311.613202212314,680
1.05
950202112315.423
4.846
202112315,370
4004
?2022
202112311.649202212312.865
????
20218??
202112314.69120221231
9.68174.0%2022123177.2%
??????
20211231151.81312.4%2022123116202220211231
123120222021%
469,497477,761(8,264)(1.7)%
68,66583,500(14,835)(17.8)%
98,955115,464(16,509)(14.3)%637,117676,725(39,608)(5.9)%1,003,391782,514220,87728.2%1,640,5081,459,239181,26912.4%
1. 202212311.9549,900
9,640
?2022
20221231
CRO
2.20928.2%10
? 1.147? 5,760? 4,760? 2,500? 2,400
202112319.9012.87729.1%2022123112.779? 1.764?4,600? 3,750
?2022
?
2,780
202112311,5806,820
433.1%202212315,2502021
202112311,5902.398202212312.23920221231
202212314,280202112311,92020221231
2017(IRC)174202211
20221231(1)17
(2)19028(3)
44.8
?2022
20211231483.164.2%20221231173.2
3.0
20211231242.616.4%20221231282.3
20211231270.219.8%20221231
216.6(1)(2)(3)
20211231587.644.0%20221231845.9
2022123120211231294.8
262.4
?2022
1231202220213290,284257,977362,5703,210611,3791,1101548103
294,781262,400
2022123120211231
123120222021184,775139,966139,168213,922
51,80671,56018,81545,66141,81759,63930,97127,307467,352558,05520211231558.116.3%20221231
467.4(i)(ii)
?2022
20221231
1231202220213,875,0374,382,887665,2512,241,962538,117629,67820222021123120152022123171
2017920221231
20211215
192.60
391.68115,055,260
?2022
20211
6.5202112
TIGIT202213
202220211231
1231202220214,382,8871,390,005(1,496,619)(1,298,723)1,077,123640,659(18,971)3,636,911(69,383)14,035(507,850)2,992,8823,875,0374,382,887
202212311520
2.239
3.7481.324
?2022
202112311315
1.1832.774
202212311116
3.2541.4371,590150202112316.40721
2.6294,3404,350850
202212311,9004.171
3.138
4,7003,7402021123136202112
344.064
9,2805,0001,6803.218
?2022
20211215217
SEC20205SEC
?2022
20221231
63,02426,27836,746117,29374,44942,844538,117328,969209,14845,94716,63229,315595,702231,697364,00516,0007,0009,00022,3275,82916,4987,7602,5535,207404,914404,914–1,811,0841,098,321712,763
202212311.173
5,530BMS6,190BMS
?2022
3.2902.091
12.5
20221231
1,900202212311,600
202212312,230
20221231
?2022
202212314.049
7,520
?
2022
NRDL
?2022
?2022
20221231202112313944550720722
20221231
?2022
10020221231210
20221231202112311.7324.831202112313
1994
(PBOC)
?2022
20052022202112318.2%2.3%
20221231
202212312021123110.3%12.3%
?2022
20221231
2022123175.2
20221231
20221231
9,000202112318,000
2022123114202110
?2022
202212315.520211231
7.2123.920211231145.8
2022123120211231
20221231
?2022
2023418
Margaret Han Dugan66Donald W. Glazer78Michael Goller48Anthony C. Hooper68Ranjeev Krishana49Thomas Malley54Alessandro Riva62Corazon (Corsee) D. Sanders66
5520101020052009BioDuro, LLCPharmaceutical ProductDevelopment Inc. 20022004Galenea Corp.19982002Telephia, Inc. 2007(The NielsenCompany)19971998Genta Inc.
(McKinsey & Company)1990619961
?2022
60201622011
20032010202019972010Howard Hughes Medical Institute20012010
George L. MacGregor2004JoyantPharmaceuticals, Inc.219719847
1991520042013
?2022
Margaret Han Dugan66202221DuganDracen2018Dracen20DuganAmericanCyanamidDuganDuganDonald W. Glazer78201322000GlazerGMOTrust2005GMO TrustGlazerProvant,Inc.2002201019921995GlazerMugar/Glazer Holdings19921993
WHDH-TV, Inc. 1997GlazerGoodwin Procter LLP19701978Ropes & Gray LLP19781992Ropes & Gray19781991
Provant, Inc.GlazerEnvironics Inc.Kronos IncorporatedReflective Technologies, Inc. Teleco Oilfield Services Inc.Glazer1966619696
19705GlazerGlazer and FitzGibbon on Legal Opinions
Massachusetts Corporation Law& PracticeGlazerMichael Goller4820154GollerBaker Brothers Investments2005Baker BrothersGoller19992003JPMorgan Partners,LLC19971999Goller(MerrillLynch and Co.)GollerDBV Technologies SA
20172019Levo Therapeutics, Inc.Goller1997520055
Goller
?
2022
Anthony C. Hooper6820201Hooper20201201892020120112018820102011HooperBristol Myers Squibb Company (BMS)20092010HooperBMS20042009HooperBMSHooperBMS
BMSHooperHooper19781988MBAHooperMannKind CorporationMNKDHooperHooper
Ranjeev Krishana4920141020202Krishana2011Baker Bros. Advisors LPBaker Bros.Krishana(Pfizer, Inc.)
Krishana200320072008201120082010KrishanaKrishana
Accenture plcKrishana19955
20016Krishana
Thomas Malley542016120075MalleyMossrock Capital, LLC1991420075MalleyJanus MutualFunds1999120075MalleyJanus Global LifeSciences FundJanus19911998Malley
JanusMalley19916MalleyKura Oncology, Inc.
2015Kiniksa Pharmaceuticals, Ltd.2016OvaScience Inc.201812Millendo Therapeutics, Inc.20122017Synageva BioPharma Corp.2015520062015Puma Biotechnology, Inc.20112015Cougar Biotechnology, Inc.2009720072009Malley
?2022
Corazon (Corsee) D. Sanders6620208Sanders(Bristol Myers Squibb Corporation)201911
20202Sanders201832019112017120183Juno Therapeutics
19942017SandersGenentechGenentech(Late StagePortfolio Committee)Genentech(Late Stage Clinical Operations)GenentechGenentechGenentech DATA
Sanders(Fred Hutchinson CancerResearch Center)(Board of Trustees)Molecular Templates Inc.MTEMLegend Biotech CorporationLEGNAltruBio Inc.AbGenomicsUltragenyx Pharmaceutical Inc.RARESanders(Magna Cum Laude)Sanders
Alessandro Riva62202221RivaIntima Bioscience,Inc.20192021
Ichnos Sciences
20172019Riva
Kite Pharma20052016Riva
GSKRivaCentury Therapeutics, Inc.iPSCNKTRivaTransgene SATNGTNG
Farmitalia Carlo ErbaRh?ne-Poulenc RorerAventis(BCIRG)(CIRG)RivaRiva
?2022
51201410(Hillhouse Capital)2005
1995720035
2023418
* 202232202243
6120184202141
2517
20184200920184201720184(Pfizer Essential Health)2004200920012004
199220082018(RDPAC)20152018
(NDPE)2017201720171993419901
?2022
522021620206
20182020(AlexionPharmaceuticals)50
20152018(Quest Diagnostics)
20072012Johnson & Johnson(J&J)(Xian-Janssen)(PepsiCo)1999(DukeUniversity)(Fuqua School of Business)1992
462021420115
2010Joyant Pharmaceuticals19962001
?2022
13.51B(1)
20221231
13.51B(1)
2022131
Margaret Han Dugan202221
20222252022913
Alessandro Riva202221
202211202022622Corazon (Corsee) D. Sanders20221120Anthony C. HooperAnthony C. Hooper20234
?2022
20221231
2010102820188806160201623BGNE20211215688235
EUSA Pharmaociperlimab
1951982023425
20221231
?2022
20221231293
2022123169.0%
18.1%202220211231
20211231
73.6%26.0%20222021123123.9%29.4%
20222021123112.0%16.2%202212315%
?
2022
2023425
20221231
Anthony C. Hooper20234172023418
?????
?2022
?????????
?2022
??????????
?2022
?
?
? 10-K?
202012
174.8515,895,001206,635,013
20.5%2,779,241,000(a)201910303036%(b)
1.007.8420191031
26%(c)2019103126%
?2022
2019112920221231
(%)
20211231
20221231
20221231
(a)
2,779,241100.00%1,869,6432,080,068699,173
(a) 12.5
20191129
2026201911120191292020132020924
20.6%
20.4%
75,000,000
?
2022
2020121(a)20%(b)60(c)
20203182020925202010
20219165,5292,151,87750,000,0002022123150,000,0002020720207152020
202,995,3382020712
14.2308185145,838,979
20.8
(a)
(b)(c)
(d)
2020713202071620221231
?2022
2021121520216162021
192.60
234.89391.68115,055,260
3,392,616,000(i)(ii)(iii)(iv)(v)
2020111620211292021420202151420216120216212021628202163020217920217282021101520211116202111232021112420211129202111302021122202112620211272021121320211221202112282022429202262720228302022928
2021430
?2022
2022123183134
20221231
20211231
20221231
20221231
13,245,940–4,499,8498,746,091467,700–376,60191,099150,000–153,451– 3,451*136,360–71,58064,7806,000,000–2,662,6743,337,3261,630,155–489,0001,141,15521,630,155–8,253,15513,377,000
*
?2022
2022123120221231296
3131
2022123111
20221231538.12021629.7
?2022
202212316.820210.7
20221231
2020317
2020924
20.6%20219
165,5292,151,87750
20221231
?2022
20221231
Margaret Han Dugan
Donald W. GlazerMichael GollerAnthony C. Hooper
Ranjeev KrishanaThomas MalleyAlessandro Riva
Corazon (Corsee) D. Sanders
(1) 202221Margaret Han DuganAlessandro Riva
(2) Anthony C. Hooper202341720221231
2023416Anthony C. Hooper* 2022131
2022622
?2022
2023202420252023Margaret Han DuganAlessandro RivaMargaret Han DuganAlessandro Riva20222Margaret Han DuganAlessandro Riva2022
2023Margaret HanDuganAlessandro Riva2026202212313.13
Anthony C. Hooper
?2022
2023327
65,00020225,0002023412022
65,000
(1)35,000
(2)17,500
(1)
30,000
(2)15,000
(1)18,000
(3)9,000
(4)20,000
(5)10,000
(6)
20,000
(5)
10,000
(6)
(1) 20225,000
(2) 202210,000
(3) 20223,000
(4) 20221,500
(5) 20222,000
(6) 20221,000
?2022
400,000
400,000202150%50%
(i)100%(ii)
100%
(i)(ii)
20162016
1,000,00020192
202120221231
21.220.6
262728
?2022
2017425800,000
100%
(i)(ii)(iii)(iv)(i)(ii)12(iii)(iv)20,000(v)2015201720
2012
?2022
201020187242018202122420211120231231
20212018
100,000202120211120231231302021
2023
20221231
20221231
?2022
20221231
20221231
20221231
8.10
?2022
20221231XV
(a)XV78
(b)352(c)
(1)
25,204,014
(2)
1.86%
9,633,361
(3)
0.71%
102,188
(4)
0.008%
7,727,927
(5)
0.57%
29,072,476
(6)
2.15%
510,941
(7)
0.04%
481,533
(8)
0.04%
1,456,052
(9)
0.11%
15,797,527
(10)
1.17%
172,372
(11)
0.01%
4,123,998
(12)
0.31%
1,127,542
(13)
0.08%
(14)
0.000004%
Margaret Han Dugan73,918
(15)
0.005%
Donald W. Glazer3,150,782
(16)
0.23%
Michael Goller413,335
(17)
0.03%
Anthony C. Hooper143,988
(18)
0.01%
Ranjeev Krishana413,335
(19)
0.03%
Thomas Malley1,326,083
(20)
0.10%
Alessandro Riva73,918
(21)
0.005%
Corazon (Corsee) D. Sanders104,117
(22)
0.008%
396,253
(23)
0.03%
?
2022
(1) 202212311,351,430,376
(2) (1)1,260,566(2)23,499,740
(3)443,708
(3) Roth IRA PENSCO
(4) The John Oyler Legacy Trust
(5)
(6) Oyler Investment LLC
Oyler Investment LLC 99%
(7) The Oyler Family Legacy Trust
(8)(9)
(10) (1)5,464,801(2)10,219,971
(3)112,755(11)
(12) Wang Investment LLCWang Investment LLC99%
?2022
(13)(14)
(15) (1)DuganDugan57,226
(2) Dugan16,692
(16) (1) Glazer2,746,729(2)GlazerGlazer
379,561(3) Glazer24,492
(17) (1) Goller17,082(2)GollerGoller379,561(3) Goller16,692
(18) (1)HooperHooper119,496
(2) Hooper24,492
(19) (1) Krishana17,082(2)KrishanaKrishana
379,561(3) Krishana16,692
(20) (1) Malley407,082(2)MalleyMalley902,309(3) Malley16,692
(21) (1)RivaRiva57,226
(2) Riva16,692
(22) (1) Sanders7,800(2)SandersSanders
79,625(3) Sanders16,692
(23) (1)379,561
(2)16,692
20221231
(a)XV7
(b)352(c)
?2022
20221231
XV23
(1)Amgen Inc.246,269,42618.22%Julian C. Baker
(2)
152,875,36311.31%Felix J. Baker
(2)
152,875,36311.31%Baker Bros. Advisors (GP) LLC
(2)
152,419,70311.28%Baker Bros. Advisors LP
(2)
152,419,70311.28%Baker Brothers Life Sciences
Capital, L.P.
(2)
139,823,42310.35%HHLR Fund, L.P.
(3)
129,433,0599.58%HHLR Advisors, Ltd.
(3)
133,587,6559.88%The Capital Group Companies,Inc.(4)
108,706,8868.04%JPMorgan Chase & Co.
(5)
13,269,7140.98%13,208,484(S)0.98%(S)1,192,9890.09%1,210,8870.09%6,5650.0005%84,543,6186.26%
(S)
(1) 202212311,351,430,376
(2) Julian C. BakerFelix J. BakerBaker Bros. Advisors (GP) LLCBaker Bros. Advisors (GP) LLC
Baker Bros. Advisors LPBBABBA667, L.P.Baker Brothers Life Sciences, L.P.Baker Brothers Life Sciences Capital, L.P.Baker Brothers Life Sciences, L.P.
BBAMichael GollerRanjeev Krishana
BBA
?2022
Baker Brothers Life Sciences Capital, L.P.2021121520211215140,543,649Baker Brothers Life Sciences, L.P.Julian C. BakerFelix J. BakerBaker Bros. Advisors (GP) LLCBBA667, L.P.11,152,058Baker Brothers Life Sciences, L.P.140,543,649723,996
BBABaker BrothersLife Sciences Capital, L.P.Baker Brothers Life Sciences, L.P.140,543,649723,996
BBAJulian C. BakerFelix J. Baker270,868FBB3 LLC151,004
(3) (i) 133,587,655HHLR Fund, L.P. YHG Investment, L.P.(ii) 13,447,603HillhouseBGN Holdings LimitedHHLR Adrisors, Ltd.YHG Investment, L.P.HHLR Fund,L.P.Hillhouse Capital Management, Ltd.Hillhouse Fund II, L.P.Hillhouse Fund II, L.P.Hillhouse BGN Holdings LimitedHHLR Adrisors, Ltd.HHLR Fund, L.P.YHG Investment, L.P. 133,587,655Hillhouse CapitalManagement, Ltd.Hillhouse BGN Holdings Limited13,447,603Hillhouse Fund II, L.P.Hillhouse BGN Holdings Limited13,447,603
(4) (i) 14,715,171Capital International, Inc.(ii) 715,234Capital International Limited
(iii) 2,129,219Capital International Sarl(iv) 87,554,010Capital Research andManagement Company(v) 198,926Capital Group Investment Management Private Limited
(vi) 3,394,326Capital Group Private Client Services, Inc.Capital Group International, Inc.Capital Research and Management CompanyCapitalInternational, Inc.Capital International LimitedCapital International SarlCapital Group InvestmentManagement Private LimitedCapital Group Private Client Services, Inc.Capital Group International,Inc.Capital Research and Management CompanyCapital GroupInternational, Inc.Capital International, Inc.Capital International LimitedCapital InternationalSarlCapital Group Investment Management Private LimitedCapital Group Private Client Services, Inc.21,152,876Capital Research and Management CompanyThe Capital Group Companies Inc.The Capital Group Companies Inc.Capital Research and Management Company103,965,748
(5) JPMorgan Chase & Co. 20221229JPMorgan Chase & Co. 100,505,09113,517,31484,540,4831,430,466646,946
20221231
XV23
?2022
2011201620182018202262220162018
20231120231
49,490,753
3.69%202291202333120182023331
1. 2011
20114152015417201120162220162011
2011
201143,560,4322016222016
201120221120112,908,2972011202211
20221231265,1092022123120234182,643,0421,688,7042023418
0.12%2011
?2022
20112011
2011
2011
0.011.85
2011
20112016222016201120112018730
?2022
2011
2022123120112402011
20115202016131202211202212312011
2022
20221231
2011520
(1)
100.01–––––201343
(1)
100.01879,267–––879,2672015629
(1)
100.50500,000–––500,000Thomas Malley2016125
(2)
101.85552,752–––552,752
201276
(3)
100.0112–––12–201343
(3)
100.0112–––122015629
(3)
100.5011–––112011520 2016131
(3)
100.01
1.85
828,937–165,113
(4)
–130663,6942011520 2016131
(3)
100.01
1.85
147,306–99,996
(5)
–447,306
2,908,297–265,109–1462,643,042
(1) 20%80%20%48
?2022
(2)
(3) 20%/25%80%/75%20%/25%48/36
(4) 1310.3720.74
(5) 1310.0812.43
2. 2016
20181172018127201620161142016
2016202041320206172016201657,200,0002016203020224172022622201620162016201666,300,000201620
2016
2016
?2022
20162022622
10%2016
30%202211201650,871,19620221120221231
51,224,485201620221231202341875,034,50474,808,6292016
2022112016140,532,00120162022112022123117,714,112202212312023418189,114,821184,187,4442023418
13.56%2016
2016
1%
?2022
(i)
1/13(ii)
2016201620162030413201672016
2022123120161,07820162016282022123120160.528.81
?
2022
20221154,065,07320162022123158,683,1442016
(1)(2)
2022
20221231
2016 1116
(3)
102.792.842,047,500––––2,047,5002017 927
(3)
106.737.70935,000––––935,0002018 430(3)
1013.3713.04996,810––––996,8102018 626(3)
1012.7012.341,310,088––––1,310,0882019 65(3)
109.259.232,193,282––––2,193,2822020 617
(3)
1013.3313.421,821,976––––1,821,9762021 616
(3)
1025.5426.53906,906–––906,9062022 622
(3)
1011.7411.98–1,887,678–––1,887,6782016 1116
(3)
102.792.841,613,430––––1,613,43020179 27
(3)
106.737.70750,000––––750,0002018 626
(3)
1012.7012.34655,044––––655,0442019 65
(3)
109.259.23747,708––––747,708
?2022
(1)(2)
2022
202212312020 617(3)
1013.3313.42560,599––––560,5992021 616
(3)
1025.5426.53241,839––––241,8392022 622(3)
1011.7411.98–471,913–––471,913Anthony C. Hooper*2020
(5)
1012.6212.2221,970––––21,9702020 617(5)
1013.3313.4245,383––––45,3832021 616(5)
1025.5426.5317,498––––17,4982022 622
(5)
1011.7411.98–34,645–––34,6452016 28
(4)
102.6115.492.42188,926–188,916–102017 62
(5)
102.9413.933.1565,988–65,988––2018 66
(5)
1015.7316.1517,442––––17,4422019 65
(5)
109.259.2364,610––––64,6102020 617
(5)
1013.3313.4245,383––––45,3832021 616
(5)
1025.5425.6317,498––––17,498Margaret Han Dugan2022
(5)
1016.4716.22–22,581–––22,5812022 622
(5)
1011.7411.98–34,645–––34,645
?2022
(1)(2)
2022
20221231Donald W. Glazer2017
419(4)
102.842.83199,992––––199,9922018 66
(5)
1015.7316.1517,442––––17,4422019 65(5)
109.259.2364,610––––64,6102020 617
(5)
1013.3313.4245,383––––45,3832021 616(5)
1025.5425.6317,498––––17,4982022 622(5)
1011.7411.98–34,645–––34,645Michael Goller2017
(4)
102.842.83199,992––––199,9922018 66
(5)
1015.7316.1517,442––––17,4422019 65
(5)
109.259.2364,610––––64,6102020 617
(5)
1013.3313.4245,383––––45,3832021 616
(5)
1025.5425.6317,498––––17,4982022 622
(5)
1011.7411.98–34,645–––34,645Ranjeev Krishana2017
(4)
102.842.83199,992––––199,9922018 66
(5)
1015.7316.1517,442––––17,4422019 65
(5)
109.259.2364,610––––64,6102020 617
(5)
1013.3313.4245,383––––45,3832021 616
(5)
1025.5425.6317,498––––17,4982022 622(5)
1011.7411.98–34,645–––34,645
?2022
(1)(2)
2022
20221231Thomas Malley2017
(5)
102.943.15169,988––––169,9882018 66
(5)
1015.7316.1517,442––––17,4422019 65
(5)
109.259.2364,610––––64,6102020 617
(5)
1013.3313.4245,383––––45,3832021 616(5)
1025.5425.6317,498––––17,4982022 622
(5)
1011.7411.98–34,645–––34,645Corazon D. Sanders
2020 824
(5)
1018.5018.2627,482––––27,4822021 616
(5)
1025.5425.6317,498––––17,4982022 622
(5)
1011.7411.98–34,645–––34,645Alessandro Riva
2022 228
(5)
1016.4716.22–22,581–––22,5812022 622
(5)
1011.7411.98–34,645–––34,6452018 41
(4)
1012.9213.8512.7263,290–63,2846–2019 65
(5)
109.259.2364,610––––64,6102020 617
(5)
1013.3313.4245,383––––45,3832021 616(5)
1025.5425.6317,498––17,498––
?2022
(1)(2)
2022
202212312017 419
(4)
102.842.83199,992––––199,9922018 66
(5)
1015.7316.1517,442––––17,4422019 65(5)
109.259.2364,610––––64,6102020 617(5)
1013.3313.4245,383––––45,3832021 616(5)
1025.5425.6317,498––––17,4982022 622
(5)
1011.7411.98–34,645–––34,645
2018 430
(6)
1013.3713.04766,599––––766,5992019 65
(3)
109.259.23797,550––––797,5502020 617
(3)
1013.4213.33756,821––––756,8212021 616
(3)
1025.5425.63483,678––––483,6782022 622
(3)
1011.7411.98–1,061,814–––1,061,8142020 630
(3)
1014.5514.66104,754––––104,7542021 616
(3)
1025.5426.53177,853––––177,8532022 622
(3)
1011.7411.98–589,888–––589,888
?2022
(1)(2)
2022
202212312016 713(3)
102.2710.662.29233,948–233,948–––2017 627
(3)
103.5010.663.49999,999–999,999–––2018 626(3)
1012.7012.34364,208––––364,2082019 65
(3)
109.259.23558,285––––558,2852020 617
(3)
1013.3313.42525,564––––525,5642021 616
(3)
1025.5426.53332,527––––332,5272022 622
(3)
1011.7411.98–707,876–––707,876
2016 92
(3)
102.262.27207,575––––207,5752017 627
(3)
103.503.49850,465––––850,4652018 626
(3)
1012.7015.3112.34122,798–78,000––44,7982019 65
(3)
109.259.23211,276––115,752–95,5242020 617
(3)
1013.3316.8513.42204,971–68,172136,799––2021 616
(3)
1025.5426.53157,196––117,897–39,299
?2022
(1)(2)
2022
202212312016713
(3)
102.272.2915,385–––15,3852016713
(3)
102.2712.292.293,247,450–16,029–13,231,4202016722
(3)
102.1313.972.10105,487–14,001–2691,4602016722
(6)
102.1314.942.10981,325–194,025–692786,6082016729
(3)
102.112.0226–––1214201689
(3)
102.042.10–––––2016822
(3)
102.282.24–––––2016912
(3)
102.332.42–––––2016919
(3)
102.512.38–––––2016926
(3)
102.352.27–––––20161012
(3)
102.4812.062.42134,498–134,492–620161012
(6)
102.4812.022.421,020–1,020––20161017
(3)
102.422.5561,399–––61,3992016111
(3)
102.562.57–––––
?2022
(1)(2)
2022
202212312016117
(3)
102.432.46–––––2016118
(3)
102.462.51–––––20161116
(3)
102.792.84–––––20161121
(3)
102.462.42–––––20161128
(3)
102.4917.482.3839,000–39,000––20161130
(3)
102.432.441,274–––1,2742016121
(3)
102.442.37–––––2016129
(3)
102.072.0934,099–––34,099201713
(3)
102.3412.632.3916,965–9,165–7,800201715
(3)
102.442.3963,661–––63,661201719
(3)
102.3716.242.43158,496–26,000–132,4962017117
(3)
102.512.53–––––2017117
(6)
102.5115.062.5388,556–41,340–47,2162017123
(3)
102.4614.332.49108,875–108,875––2017130
(3)
102.802.62–––––
?2022
(1)(2)
2022
20221231201721
(3)
102.682.77144,989–––144,989201726
(3)
102.762.7632,201–––32,201201728
(3)
102.672.78–––––2017213
(3)
102.7713.822.7771,643–31,200–40,4432017227
(3)
102.972.93–––––201736
(3)
103.143.06–––––2017313
(3)
103.0815.193.02142,701–26,000–116,7012017320
(3)
103.043.0484,968–––84,9682017327
(3)
102.792.79–––––2017331
(6)
102.8115.602.8285,683–44,278–41,405201743
(3)
102.8213.992.825,928–5,928––2017410
(3)
102.862.91–––––2017411
(3)
102.912.95–––––2017417
(3)
102.9213.912.95109,590–98,163–11,4272017424
(3)
102.822.89–––––
?2022
(1)(2)
2022
202212312017426
(3)
103.013.09–––––201751
(3)
103.1415.863.13531,245–270,582–260,663201752
(6)
103.1313.943.12115,349–10,244416104,689201753
(3(3)
103.123.1211,999–––11,999201758
(3)
103.022.98–––––2017510
(3)
102.882.92–––––2017515
(3)
102.812.909,100–––9,1002017530
(3)
102.882.8821,060–––21,060201761
(6)
102.8314.682.941,150,045–55,8485071,093,6902017612
(3)
102.9910.693.0012,844–117–12,7272017614
(3)
103.0414.123.05776,581–192,686–583,8952017615
(6)
103.0514.643.044,029,896–872,98910,0882,5353,144,2842017621
(3)
103.313.4517,784–––17,7842017623
(3)
103.413.45–––––2017627
(3)
103.5011.753.492,233,309–49,296–2,184,013
?2022
(1)(2)
2022
202212312017629
(3)
103.503.4543,654–––43,6542017710
(3)
105.4013.765.45156,624–149,864–6,7602017717
(3)
105.6714.194.1941,106–41,106––2017717
(6)
105.6715.394.19366,366–73,541–292,8252017724
(3)
105.955.65–––––2017731
(3)
105.5815.505.42119,574–14,9114,66799,9962017731
(6)
105.5813.755.42371,072–34,801–336,271201781
(3)
105.4213.755.58473,200–317,200–156,000201782
(6)
105.585.45–––––201783
(3)
105.455.5119,994–––19,994201787
(3)
105.5616.155.95114,309–16,809–97,500201788
(3)
105.956.0312,649–––12,6492017810
(3)
105.955.59–––––2017811
(3)
105.595.46–––––2017817
(3)
105.3912.095.3218,317–18,317––
?2022
(1)(2)
2022
202212312017825
(3)
105.385.29–––––2017828
(3)
105.295.2824,167–––24,1672017831
(3)
105.305.30–––––2017831
(6)
105.3014.795.30281,242–96,0964,550180,596201795
(3)
105.785.68269,997–––269,9972017912
(3)
105.395.43–––––2017913
(3)
105.435.82–––––2017918
(3)
106.226.3722,269–––22,2692017922
(3)
106.5316.626.5590,155–21,567–68,5882017925
(3)
106.5511.726.56153,569–31,577–121,9922017926
(3)
106.568.71–––––2017929
(3)
107.497.9637,492–––37,4922017111
(3)
107.106.84226,356–––226,35620171130
(3)
106.386.1510,764–––10,764201815
(3)
107.727.5819,071–––19,071
?2022
(1)(2)
2022
202212312018131
(3)
109.5213.3410.4484,385–4,368–80,0172018228
(3)
1011.6111.047,904–––7,9042018430
(3)
1013.3713.0417,407––2,9908,2686,1492018626
(3)
1012.7015.1512.34935,961–74,9321,79413,091844,5712018629
(3)
1011.9011.8312,103–––12,1032018831
(3)
1013.6713.6613,741–––13,7412018831
(7)
1013.6713.66108,537–––108,5372018928
(3)
1013.2813.2565,433–––65,4332018928
(8)
1013.2813.2539,260–––39,26020181130
(3)
1011.0711.7911,028–––11,02820181231
(3)
1010.5316.2310.79144,053–6,6824,108133,26320181231
(8)
1010.5310.7912,727–––12,7272019125
(3)
109.6210.4438,649–––38,6492019228
(3)
1010.7715.1310.54130,754–107,7187,43615,600201935
(3)
1011.6811.5178,494–––78,494
?2022
(1)(2)
2022
202212312019510
(3)
109.3310.3244,213–––44,213201965
(3)
109.2514.319.233,074,162–524,186249,2491,6512,299,0762019628
(3)
109.679.5338,714––24,60914,1052019830
(3)
1011.1411.0697,201–––97,20120191129
(3)
1015.7115.8339,221––14,10525,116–20191231
(3)
1012.8012.9229,523––13,68915,834202033
(3)
1012.6215.0812.1920,657–7,80012,857–2020331
(3)
109.659.67294,775–––294,7752020512
(3)
1012.5615.1912.1838,597–23,92014,677–2020529
(3)
1012.4913.0812.7321,281–11,5059,776–2020617
(3)
1013.3315.2613.422,220,140–92,690484,66699,5411,543,2432020630
(3)
1014.5514.66212,771–––212,771202087
(3)
1017.2416.9940,248–––40,2482020831
(3)
1018.6918.8514,040––8,5285,512–2020930
(3)
1021.6522.038,021–––8,021
?2022
(1)(2)
2022
202212312020116
(3)
1023.0823.07175,708–––175,70820201130
(3)
1021.9920.9926,962––5,9155,29115,7562021122
(3)
1027.4628.8164,441––6,8902,28855,2632021226
(3)
1025.3625.816,331–––6,3312021331
(3)
1025.6126.78158,834––7,5142,496148,824202157
(3)
1024.1524.7884,240–––84,2402021528
(3)
1027.0027.58121,485–––121,4852021616
(3)
1025.5426.532,333,955––408,09686,4371,839,3962021630
(3)
1027.4827.2888,829––29,43259,397202186
(3)
1025.8425.61158,262––7,839150,4232021831
(3)
1023.2223.72153,322–––153,3222021930
(3)
1027.8128.7361,230––4,21257,0182021115
(3)
1028.3828.0845,786–––45,78620211130
(3)
1026.4026.8564,649–––64,64920211231
(3)
1021.0320.8459,332–––59,332
?
2022
(1)(2)
2022
202212312022127
(3)
1017.2718.61–371,059––371,0592022228
(3)
1016.4716.22–171,626––171,6262022331
(3)
1015.8515.46–135,694––135,694202256
(3)
1012.2712.50–80,821––80,8212022531
(3)
1010.3010.56–123,604––123,6042022622
(3)
1011.7411.98–6,111,027–294,3375,816,6902022622
(9)
1011.7411.98–11,804––11,8042022630
(3)
1012.4812.81–77,974––77,974202285
(3)
1014.7014,96–188,929––188,9292022831
(3)
1012.7313.32–22,009––22,0092022930
(3)
1010.4810.58–66,690––66,69020221110
(3)
1013.5614.52–54,106––54,10620221130
(3)
1013.8414.74–17,745––17,74520221230
(3)
1017.2217.26–7,592––7,592
54,065,07312,516,8165,623,2802,022,498252,96758,683,144
?2022
* Anthony C. Hooper2023417
(1) 13
(2) 13
(3) 25%
75%25%36(4)(5)
(6) 20%80%20%48
(7) 48(8)
(9) 50%50%50%12
?2022
2016
(3)
1,887,6782022622(1)11.98–11.7411,999,969
471,9132022622(1)11.98–11.742,999,951Anthony Hooper34,6452022622(2)11.98–11.74199,967Margaret Han Dugan22,5812022228(2)16.22–16.47149,037Margaret Han Dugan34,6452022622(2)11.98–11.74199,967Donald W. Glazer34,6452022622(2)11.98–11.74199,967Michael Goller34,6452022622(2)11.98–11.74199,967Ranjeev Krishana34,6452022622(2)11.98–11.74199,967Thomas Malley34,6452022622(2)11.98–11.74199,967Corazon D. Sanders34,6452022622(2)11.98–11.74199,967Alessandro Riva22,5812022228(2)16.22–16.47149,037Alessandro Riva34,6452022622(2)11.98–11.74199,967
34,6452022622(2)11.98–11.74199,967
1,061,8142022622(1)11.98–11.746,749,952
589,8882022622(1)11.98–11.743,749,918
707,8762022622(1)11.98–11.744,499,968
7,440,680
2022127
20221230(1)
10.56
18.61–
10.30
17.2748,008,319
12,516,81680,105,854
(1) 25%
75%25%36
?2022
(2)(3)201620221231201613,150
201620179262022123120221135,546,446201620221231201655,397,173
2022
20221231
2022(1)
201843013.37143,754–143,754––12.19201862612.7047,086–47,086––12.02202161625.54146,250–36,556–109,69410.52202262211.74–334,009––334,009–201862612.7023,543–23,543––12.02202161625.5439,000–9,750–29,25010.52202262211.74–83,499––83,499–Anthony C. Hooper202161625.547,800–––7,800–
202262211.74–16,692––16,692–202161625.547,800–7,800––10.52Margaret Han Dugan202262211.74–16,692––16,692–Donald W. Glazer202161625.547,800–––7,800–
202262211.74–16,692––16,692–
?2022
2022
20221231
2022(1)
Michael Goller202161625.547,800–7,800––10.52
202262211.74–16,692––16,692–Ranjeev Krishana202161625.547,800–7,800––10.52
202262211.74–16,692––16,692–Thomas Malley202161625.547,800–7,800––10.52
202262211.74–16,692––16,692–Corazon D. Sanders202161625.547,800–7,800––10.52
202262211.74–16,692––16,692–Alessandro Riva202262211.74–16,692––16,692–
202161625.547,800––7,800––
202161625.547,800–7,800––10.52
202262211.74–16,692––16,692
?
2022
2022
20221231
2022
(1)
201843013.37459,979–229,970–230,00912.192019659.25216,736–108,368–108,36810.58202061713.33100,620–33,527–67,09310.29202161625.5478,000–19,500–58,50010.52202262211.74–187,876––187,876–202063014.5541,405–13,793–27,61212.48202161625.5428,678–7,163–21,51510.52202222816.47–61,750––61,750–202262211.74–104,377––104,377–201862612.7013,104–13,104––12.022019659.2537,947–18,954–18,99310.68202061713.3369,875–23,283–46,59210.29202161625.5453,625–13,403–40,22210.52202262211.74–125,255––125,255–
?2022
2022
20221231
2022(1)
201862612.7011,141–11,141––12.022019659.2531,434–15,70415,730–10.68202061713.3336,335–12,10324,232–10.29202161625.5425,350–6,33119,019–10.52
2018131 20211231
18.5533,848,542–11,219,7154,422,86018,205,967(2)202211 20221231
12.46–37,617,8532,9382,276,46935,338,446(3)201924 20211231
12.0123,842–15,158–8,684(4)202211 20221231
17.70–42,82219,188–23,634(5)
35,546,44638,707,66912,090,8326,766,11055,397,173
(1) 13
(2) 1310.1016.92
(3) 1316.92
(4) 1310.1016.92
(5) 1316.92
?2022
(4)
334,0092022622(1)–11.743,999,886
83,4992022622(1)–11.74999,933Anthony C. Hooper16,6922022622(2)–11.74199,893Margaret Han Dugan16,6922022622(2)–11.74199,893Donald W. Glazer16,6922022622(2)–11.74199,893Michael Goller16,6922022622(2)–11.74199,893Renjeev Krishana16,6922022622(2)–11.74199,893Thomas Malley16,6922022622(2)–11.74199,893Corazon D. Sanders16,6922022622(2)–11.74199,893Alessandro Riva16,6922022622(2)–11.74199,893
16,6922022622(2)–11.74199,893187,8762022622(1)–11.743,999,886
61,7502022228(1)–16.47999,970104,3772022622(1)–11.744,999,873125,2552022622(1)–11.745,999,945
37,617,853
2022131
20221230(1)–
10.48
16.38458,791,912
42,822
2022131
20221230(3)–
16.38
17.22757,899
38,707,669482,348,341
(1) 25%
(2)(3)(4)
?2022
3. 2018
20181172018127201820186620182019652018
202162018
202191
2018201815%20182018
201820185%2018
1%10%25,000
?2022
31912018
85%
2018
2018
?2022
20187,355,31520221120185,194,546202211
2021911,528,475201820221231
20234183,666,0712,735,219201820221231202212312022
20187,355,31520221120185,194,5462021912022311,528,47520182022123120234183,666,0712,735,21920234180.20%20182018
2018201812720185.520182021912022312022912,9923,1063,039
2018
?2022
2018
202231202191
202191202231
(1)(2)
202191613.7610,6236,800
13.76
202191202231
611.22
13.76
15,1178,317
11.22
6,800
13.76
202191
202231
611.22
13.76
20,538,3829,169,704
13.76
666,1729,659,016
11.22
860,5749,667,337
1. 20219120223123.7216.20184.71
126.404,107,06031,956,623
5,284,67541,290,4342021912022312018
?2022
2. 202191202231
20182022228202283113.7611.221,528,475
2022228202283116.4712.73
128.5999.9010,803,88684,351,98811,373,33389,260,078
3. 20229110,512,096
930,852
4. 2018
4. 2018
201866201812,000,0002018
202262220162018
201820
2018
?2022
5635(c)(4)2018
201812,000,00020221120189,344,65920221231201820182022622
202212312023418
0020234180%2018
20221120189,881,71520221231
2018452,58220182022622202212312018202212312023418
0020234180%2018
2018
20182022622201620182018
2018
1%
?2022
(i)
1/13(ii)
20182018
(1)(2)
2022
20221231
2018831
(3)
1013.6714.0513.6630,9019,82821,073
30,9019,82821,073
?2022
(1) 13
(2) 13
(3) 25%
75%25%36
Thomas MalleyAnthony C. HooperCorazon (Corsee) D.Sanders20221231Thomas MalleyCorazon (Corsee) D. Sanders
Anthony C. HooperThomas Malley
20221231
?2022
13.2013.2113.22
2023418
2018882022
2022323
20212022323Ernst & Young LLP
20221231
Ernst & Young LLP2023
2023418
?2022
20221231
2022
C.2.1
Ranjeev Krishana
?2022
3.21D.3.3D.3.7
Thomas MalleyAnthonyC. Hooper2023417Corazon (Corsee) D. SandersThomas Malley3.10(2)3.21
3.25E.1.2
Margaret Han DuganRanjeev KrishanaMargaret Han Dugan
20226222022913Margaret Han Dugan
B3.1
Donald W. GlazerMichael GollerAnthony C. Hooper2023417Alessandro RivaDonald W. Glazer
?2022
20221231
B.8
202211
?2022
20221231
*Margaret Han DuganDonald W. GlazerMichael GollerAnthony C. HooperRanjeev KrishanaThomas MalleyCorazon (Corsee) D. SandersAlessandro Riva* Anthony C. Hooper202341720221231
2023416Anthony C. Hooper2022131
2022622
?2022
2022
3.13
20232024
2025
?2022
?2022
???????
10-K???
?2022
??
Thomas MalleyAnthony C. HooperCorazon (Corsee) D.SandersThomas MalleyAnthony C. HooperCorazon (Corsee) D. SandersAnthony C. Hooper2023417202212312023416Anthony C. HooperThomas Malley
3.10(2)3.21Anthony C. Hooper
Corazon (Corsee) D. Sanders3.10(2)3.21
2022123113
www.beigene.comHKEX investors2022
202120222022
????
?2022
?????????
Margaret Han DuganRanjeev KrishanaMargaret HanDugan2022622
2022913Margaret Han Dugan2022123126
25,000,001105,000,000
?2022
20221231271www.beigene.comHKEXinvestors2022
??????
Donald W. GlazerMichael GollerAnthony C. HooperAlessandro RivaDonald W. Glazer2022131
202221Alessandro Riva
?2022
20221231 www.beigene.comHKEX investors
20222022
3.13
???
20221231271MargaretHan DuganMichael GollerThomas MalleyAlessandro RivaCorazon (Corsee) D.SandersAlessandro Riva20221120Alessandro RivaCorazon (Corsee) D. Sanders www.beigene.comHKEX investors
?2022
????
20221231
Anthony C. HooperMargaret Han DuganRanjeev KrishanaCorazon (Corsee)D. SandersAnthony C. Hooper2022225Margaret Han Dugan2022622 www.beigene.comHKEX investors
?2022
20202022 www.beigene.comHKEX investors
2023418
LGBTQ+1
2022
202124%202233%52%
2023425
?2022
2021
?2022
(Mourant Governance Services (Cayman) Limited, 94 Solaris Avenue, CamanaBay,Grand Cayman KY1-1108, Cayman Islands(a)(b)
193414a-8(b)(2)(c)(d)(e)(f)(i)(ii)
(g)
?
2022
A.2.1
20221231
?2022
20221231
*7/71/1Anthony C. Hooper
(5)
7/713/134/41/17/74/41/1(4)
2/73/52/40/1Margaret Han Dugan
(2)
7/71/54/43/41/1Donald W. Glazer7/71/1Michael Goller7/74/41/1Ranjeev Krishana7/75/54/41/1Thomas Malley7/711/134/41/1Alessandro Riva
(3)
7/74/41/1Corazon (Corsee) D. Sanders7/713/134/44/41/1
(1)
6/75/53/41/1
* 20221231
20221231
(1) 2022131
(2) 202221Margaret Han Dugan
2022225Dugan2022913Dugan
?2022
(3) 202221Alessandro Riva
20221120Alessandro Riva
(4) 2022622
(5) Anthony C. Hooper2023417
C.2.720221231
2022123120221231
?2022
202221Margaret Han DuganAlessandro Riva20221DuganRiva20221231Anthony C. HooperMargaret Han DuganDonald W. GlazerMichael GollerRanjeev KrishanaThomas MalleyAlessandro RivaCorazon (Corsee) D. Sanders
202220211231Ernst& Young LLP
202220217,0377,22757–7,0947,22710-Q2022
?
2022
201910312020
???
18.2%14A14A
???
?
12.5
LUMAKRAS
?
(sotorasib)
?2022
sotorasib (AMG 510)
AMG 51020232(i)2023112023831AMG 510(ii)AMG 510
14A.52
14A.53(1)14A.5214A.53(1)(a) 14A(b)(c)(d)
14A.5514A.56(e) 2019111
?
2022
(a)
= 50% x(b)?
(i)(ii)(iii)(x)
(y)20AMG
= x?
= x
?2022
12.5
1,2503,750
(a)(b)(c)
14A.563000
2022123120221231(a)(b)
(c)
?2022
20203172020924
20.6%
20.4%(i)
(ii)2020121(a)
20%(b)60(c)2023121
20203182020925202010
20219165,5292,151,87750,000,0002022
?2022
202092473,640,000500,000,00014,728,000100,000,00058,912,000400,000,000200,000,000(i)2021119(ii)2021108
(i)2022119(ii)2022101013,980,000100,000,000
14A16
2022123114A.71
2,069,546
399.43137
2022123128
?2022
14A
Committee of Sponsoring Organizations of the Treadway Commission2013
?2022
?2022
????
(i)(ii)
?2022
20221231
D.2.3
Chan Lee202212313.29
6162
?2022
(MourantGovernance Services (Cayman) Limited, 94 Solaris Avenue, Camana Bay, Grand Cayman KY1-1108,Cayman Islands
(Mourant Governance Services (Cayman) Limited, 94 Solaris Avenue, CamanaBay, Grand Cayman KY1-1108, Cayman Islands[]
(i)(ii)(iii)(iv)(v)(vi)
20232022
?2022
290396
20221231
20221231
?2022
20221231
1,640.520221231
139.2
?2022
?
2022
?
???
?2022
??
2023329
?2022
123120222021
3,869,5644,375,678 5196328 6665,2512,241,962 7173,168483,113 8282,346242,626 14216,553270,173
5,207,0787,613,880
55,2776,881 11845,946587,605 10109,960117,431 1240,61646,679 14170,413163,049
1,172,212921,6456,379,2908,535,525
15294,781262,400 14467,352558,055 4213,861187,414 1325,18921,395 1024,04121,925 4114,335120,801 16328,969427,565
1,468,5281,599,555
?2022
123120222021 16209,148202,113 442,026220,289 1034,51743,041 1315,99614,169 4179,625269,561 1446,09554,234
527,407803,4071,995,9352,402,962
0.0001 9,500,000,00020221231 20211231 1,356,140,1801,334,804,281135133 11,540,97911,191,007 21(77,417)17,950 (7,080,342)(5,076,527)
4,383,3556,132,5636,379,2908,535,525
?2022
123120222021
171,254,612633,987 4161,309542,296 1,415,9211,176,283 286,475164,906 1,640,5081,459,239 1,277,852990,123 12751750 3,205,5862,615,018
(1,789,665)(1,438,735) 52,480(15,757) 6(223,852)15,904
(1,961,037)(1,438,588)1342,77819,228
(2,003,815)(1,457,816)19(1.49)(1.21)191,340,729,5721,206,210,049 (19.43)(15.71)
103,133,04492,785,388
?2022
123120222021(2,003,815)(1,457,816) 21(90,421)13,714 243651,865 21(5,311)(4,571)
(2,099,182)(1,446,808)
?2022
123120222021
(2,003,815)(1,457,816) 66,27846,457 20303,162240,712 468,66583,500 4(96,402)(112,486) 621,996(7,632) 2,0593,377 9,04723,510 304,112(423,019) (56,689)(153,333) (3,282)(107,128) (4,352)20,008 45,627140,044 (151,816)407,703 (1,209)(2,620)
(1,496,619)(1,298,723) (325,434)(262,942) (1,485)(2,147,881) 1,563,6183,146,891 (143,665)(8,500) 12–(43,409) 6(15,911)(43,500)
1,077,123640,659
?2022
123120222021
22–3,392,616 22–50,000 1637,37216,838 16313,774406,449 16(417,081)(321,754) 46,96492,762
(18,971)3,636,911(69,383)14,035(507,850)2,992,8824,382,8871,390,0053,875,0374,382,887 3,869,5644,375,678 196328 5,2776,881 29,50015,695 25,16929,967 95,34653,197 –75,000
?2022
202012311,190,821,9411187,414,9326,942(3,618,711)3,803,281
115,055,260123,392,604––3,392,616 2,151,877–50,000––50,000 28,778,893392,759––92,762
(2,003,690)–––––
––240,712––240,712–––11,008–11,008––––(1,457,816)(1,457,816)202112311,334,804,28113311,191,00717,950(5,076,527)6,132,563
––(152)––(152)1,375,621––––– 19,960,278246,962––46,964
––303,162––303,162
–––(95,367)–(95,367)
––––(2,003,815)(2,003,815)202212311,356,140,18013511,540,979(77,417)(7,080,342)4,383,355
?
2022
1.
?
(BTK)
?PD-1
?
PARP1PARP2???
2,7005080
18,000
CMOs2010299,000
?2022
1.
2022123148
BeiGene 101–100%BeiGene AUS Pty Ltd BeiGene Australia
56,947,230100%BeiGene Austria GmbH35,000100%BeiGene (Beijing) Co., Ltd. BeiGene Beijing
*1,922,787,023100%BeiGene Biologics Co., Ltd. BeiGene Biologics
*14,540,000,000100%BeiGene (Canada) ULC100100%BeiGene ESP, S.L.U.3,000100%BeiGene France Sarl7,500100%
*12,490,389,800100%
*263,000,000100%BeiGene Germany GmbH25,000100%
?2022
BeiGene (Hong Kong) Co., Limited
13,700,000,000
100%
*4,000,000100%
BeiGene International GmbH20,000100%BeiGene (Italy) S.r.l.10,000100%BeiGene Brazil Ltda.2,450,190100%BeiGene Poland sp. z o.o.5,000100%BeiGene South Africa Pty Ltd.–100%BeiGene Sweden AB25,000100%BeiGene Turkey Medical Products Trade Limited Company
10,000100%BeiGene Ireland Limited BeiGene Ireland
–100%BeiGene Japan, Ltd.1,781,660100%BeiGene Korea Y.H.145,000,000100%BeiGene Netherlands B.V.–100%BeiGene NZ Unlimited BeiGene NZ, Limited
100,000100%BeiGene Pharmaceuticals GmbH20,000100%
1.
?2022
*3,800,000100%BeiGene Pharmaceuticals Israel Ltd.10,000100%
*7,000,000100%
*1,000,000100%
*1,434,344,311100%
*1,000,000100%
*270,000,000100%BeiGene Singapore Pte. Ltd.1100%
*3,673,218,389100%BeiGene Switzerland GmbH BeiGene Switzerland
20,000100%168,000,000100%BeiGene UK, Ltd.BeiGene UK143100%BeiGene United Kingdom, Ltd.110100%BeiGene USA, Inc.BeiGene USA1100%BeiGene US Holdings, LLC54,000,000100%
1.
?2022
BeiGene US Manufacturing Co., Inc.210,000,000100%BeiGene Hopewell Urban Renewal, LLC
125,000,000100%Pi Health, Ltd.22,500,000100%Pi Health USA, LLC5,000,000100%Pi Health Brasil Consultoria Ltda.–100%B10 Health Technologies Private Limited
370,344,475100%Newco 101–100%
*
2.
2020MapKure, LLCMapKure20206MapKure
6202011
1.
?2022
2.
?2022
2.
?2022
2.
?
?
?2022
2.
?
?
?
?2022
2.
842-20-2520221231
?2022
2.
201720192021
20183620202022
?2022
2.
202220211231
202220211231
?2022
2.
202220211231
820820
820(1)(2)(3)
?2022
2.
202220211231
20221231
758,114
665,251
3,307706 3,000
5,190
1,426,6727068,190
20211231
107,855 315,564
2,241,962
23,80910,306
2,689,19010,306
?2022
2.
Leap Therapeutics, IncLeap2020120219LeapLeap1Leap
202220211231
(i)(ii)(iii)(iv)(v)
?2022
2.
???EUSA Pharma
100%
?
?
4590
?2022
2.
NRDL
606808
?2022
2.
?2022
2.
(i)(ii)
(i)(ii)
(iii)(iv)(v)
?2022
2.
202220211231
?2022
2.
20222021123138,118,00044,593,000202212313,169,000
20222021123158,0001,759,000202212311,664,000
?2022
2.
718718
718505505-50
?2022
2.
50%
?2022
2.
?2022
2.
2022202112313,869,564,0004,375,678,000
202220211231665,251,0002,241,962,000202220211231202220211231173,168,000483,113,000
20221231ASD SpecialtyHealthcare18.1%15.5%14.2%12.1%2022123157.0%20221231
?2022
2.
20211231
26.0%19.9%16.7%2021123123.4%202112312021123166.4%Ociperlimab
300,000,000
?2022
2.
1994
2005721202220211231
8.2%2.3%
?2022
2.
20222022102022930
?2022
2.
9910820221231122021
1319
2021112021-10832
20211215202211
?2022
3.
20212
20211231
110,424(110,424)–1,032,069(110,424)921,6458,645,949(110,424)8,535,525(4,966,103)(110,424)(5,076,527)6,242,987(110,424)6,132,5638,645,949(110,424)8,535,525
20211231
(25,234)44,46219,228(1,413,354)(44,462)(1,457,816) (1.17)(0.04)(1.21)
(15.23)(0.48)(15.71)
?2022
3.
20211231
(1,413,354)(44,462)(1,457,816)(1,402,346)(44,462)(1,446,808)
20211231
(1,413,354)(44,462)(1,457,816) (41,085)44,4623,377 (1,298,723)–(1,298,723)
20201231(3,552,749)(65,962)(3,618,711)3,869,243(65,962)3,803,281
(1,413,354)(44,462)(1,457,816)(1,413,354)(44,462)(1,457,816)20211231(4,966,103)(110,424)(5,076,527)6,242,987(110,424)6,132,563
?2022
4.
20221231
202220211231
123120222021–484,64646,82253,671104,9943,9799,493–161,309542,296
?2022
4.
20211
650,000,0001,300,000,000250,000,000
(1)(2)
(3)
?2022
4.
650,000,000
484,646,000165,354,000
?2022
4.
2021123120211231
20222021123139,655,00053,421,00020221231
9,493,000
202112
TIGIT
?????2022
?2022
4.
20221300,000,000202320232023600,000,000700,000,000
745,000,0001,150,000,000
50%25%
(1)
(2)(3)
(4)
?2022
4.
300,000,000
71,980,000213,450,00014,570,000
?2022
4.
202220211231
104,994,0003,979,0002022202112317,167,000250,000
201910
???
202012
?2022
4.
????XGEVA
?
201920201120207
?202012
?B20217
?(R/R)20224
?CD19B
1,250,000,000KRAS G12CLUMAKRAS?(sotorasib)AMG 510AMG 510HGRAC20202022AMG510
AMG 51020232(i)2023112023831AMG 510(ii)AMG
?
2022
4.
808100%
20191031202012174.8515,895,001
20.5%
Anthony Hooper20201202312022420
?2022
4.
132.74
2,109,902,000601,857,000
2,779,241,0002,162,407,000616,834,00020201231
202012312,162,407
616,8342,779,241
?2022
4.
202220211231
12312022202198,955115,46496,402112,486 195,357227,950
20221231595,7022022123120211231
123120222021114,335120,801179,625269,561293,960390,362
?2022
4.
202220211231
1231202220215,8981,893(54,865)(45,152)(1,216)423(50,183)(42,836)20222021123171,720,000110,303,0002022123120211231
54,064,000106,790,0002022123118.2%14A
?2022
4.
202220211231
12312022202168,66583,5005,50015,000
–43,39474,165141,894
202212
LY0100520221248,665,000
30,000,000
?2022
4.
Shoreline Biosciences, Inc.
20216Shoreline BiosciencesInc.ShorelineShorelineiPSCShorelineShorelineShorelineShoreline2022145,000,000
202112
202112
LBL-007LAG-3
2022130,000,000742,000,000
20211231
EUSA Pharma20201EUSA PharmaEUSA
??
βEUSA??EUSA40,000,000120,000,000
202012312021
??EUSA
?
?2022
4.
Assembly Biosciences, Inc.
20207Assembly Biosciences, IncAssemblyAssembly
AssemblyABI-H0731ABI-H2158ABI-H3733AssemblyAssembly40,000,000
503,750,000Assembly
20201231
20208?(BAT1706)
?20209102020918
?20201020,000,000145,000,00020201231202111
?
?2022
4.
202220211231
5.
20221231202112315,473,0007,209,000
?2022
6.
20221231
674,262–9,011665,251674,262–9,011665,25120211231
2,245,662–3,7002,241,9622,245,662–3,7002,241,962202212312022123120221231
?2022
6.
Leap Therapeutics, Inc. (Leap)20201Leap5,000,000Leap BB20203LeapLeap20219Leap7,250,000
Leap20221231Leap
7.4%11.7%
20222021123130,102,0009,386,000
2022123120211231
123120222021Leap3,30723,809Leap70610,306
202212312021123157,054,00043,722,00020221231
5,065,00020211231
?2022
6.
202212312021123127,710,00022,955,0002022202112313,682,0001,796,0007.
123120222021173,379483,528
(211)(415)
173,168483,11330120
1231202220216172,633483,113612535–
173,168483,113
?2022
7.
12312022202111415112
(219)309
1–14(6)12312114158.
12312022202188,95778,14020,8869,397172,503155,089282,346242,626
?2022
9.
(CTA)(MAA)20173
200,000,00095%100,000,0005%201737
900,000,00020199
100%
95%
?2022
9.
20209
5%28,723,000195,262,0002020119,116,000
100%
19,599,000132,061,000900,000,00036,558,000249,140,000
200,000,000120,000,00080,000,000202010
80,000,000118,320,0002021109198,320,000200,000,000
73,640,000500,000,00014,728,000100,000,00058,912,000400,000,00020211231
15,693,000100,000,000202211
?2022
10.
503630
12312022202125,93822,5366,8344,8921,2991,82334,07129,251
12312022202156,00860,76253,95256,669109,960117,431
24,04121,92534,51743,04158,55864,966
?2022
10.
2023123126,2782024123121,6472025123111,312202612312,82120271231966
63,024(4,466)58,558
12312022202128,06419,96222,27837,454
123120222021
5.76%5.15%
?2022
11.
12312022202165,48565,485158,908118,20353,78650,288222,448144,083175,679119,585
47,48327,404723,789525,048(171,470)(124,286)293,627186,843845,946587,60520211175,197,00042
?2022
11.
202220211231
123120222021224,39290,229
33,33263,36112,25617,17823,64716,075293,627186,84320222021123162,302,00044,742,000
12.
2022123120211231
2022123120211231
7,500(4,000)3,5007,500(3,250)4,25041,235(4,119)37,11643,394(965)42,429816(816)–816(816)–49,551(8,935)40,61651,710(5,031)46,679
?2022
12.
2018920202
20242
1231202220213,2259657517503,9761,71520221231123120233,1707503,92020243,1707503,92020253,1707503,92020263,1707503,92020273,1705003,670202821,266–21,266
37,1163,50040,616
?2022
13.
123120222021(583,610)(606,752)67,74434,923(1,445,171)(866,759)(1,961,037)(1,438,588)
123120222021
27,90515,2524,844(9)6,54780539,29616,0483,4804,919
–(35)2(1,704)3,4823,18042,77819,228
?2022
13.
123120222021(1,961,037)(1,438,588)
25%25%(490,259)(359,647)288,133185,87430,598(2,826)33,872(27,411)229,550254,768(49,116)(31,530)
42,77819,228(2.2)%(1.3)%
123120222021 97,89684,766 862,214625,114 19,70014,982 86,00082,060 798,563937,069 10,34811,571 63,156– (10,098)(11,322)
1,927,7791,744,240 (1,943,775)(1,758,409)
(15,996)(14,169)
?2022
13.
20221231202220211231229,550,000254,768,0002022202112315,077,247,0003,644,981,000
20221231202420321,633,101,000202520293,397,529,000
26,079,000108,861,000
20362042202220211231
123120222021119,9257,123
––––1,6302,802––123111,5559,925
?2022
13.
2022123112
202220211231
202212312013202220122022
2018202220152022
201220222025202212313,894,0000.0120221231
2,379,000
?2022
14.
12312022202171,48887,23920,47858,57922,77712,0103,0395,0523,6641,69558,95078,538
1,5102,98234,64724,078216,553270,173
123120222021
10910922,02514,140
(1)48,64224,237
80417,1627,0546,60991,779100,792170,413163,049
(1)
?2022
14.
123120222021184,775139,966139,168213,92251,80671,56018,81545,66141,81759,63930,97127,307467,352558,055
12312022202138,17646,3527,7607,8141596846,09554,234
?2022
15.
2022123120211231
1231202220213290,284257,977362,5703,210611,3791,1101548103
294,781262,400
16.
202220211231
123120222021201844580,0009202744(1)7,25050,0001,2558,0002020122(2)92029120(2)1,45010,0001,56910,0002020119378,00092029118(3)5,43737,500––2020924200,000(4)4.3%150,0001,034,554200,0001,274,5352020924500,000(5)4.5%––15,693100,000202222550,000120232252.2%50,000344,851––
(6)114,832792,000209,0481,332,197
328,9692,268,905427,5652,724,732
?2022
123120222021201844580,0009202744(1)75,395520,00089,444570,0002020122(2)92029120(2)49,369340,50053,353340,0002020119378,00092029118(3)47,847330,00059,316378,0002022729480,000102032728(7)36,537252,000––
209,1481,442,500202,1131,288,000
1. 202212314.7%202212311,171,0008,000,000
2. 2020122
1,100,000,000
202012311,100,000,000350,000,000202212314.4%202212311,484,00010,000,000201733
3. 202212314.0%
4. 20209200,000,000120,000,000
80,000,000
202110820211082022108202293020221010
200,000,000150,000,000
16.
?2022
16.
5. 2020973,640,000500,000,000
14,728,000100,000,00058,912,000400,000,000(i)2021119
(ii)2021108(i)2022119
(ii)2022101013,980,000100,000,000Hillhouse CapitalHillhouseCapitalHillhouse Capital
6. 20221231
2,435,000,0002021119202391820221231113,774,000792,000,00020221231200,446,0001,332,197,00020221231
2.6%
7. 20227
480,000,000202212314.2%
2022123137,372,000252,000,000
20221231
20231231328,9692024123129,4122025123135,1362026123144,6972027123144,697
55,206538,117
?2022
16.
20222021123121,699,00029,263,0002,594,0001,054,00017.
?????????
202220211231
1231202220211,438,440748,824
(183,828)(114,837)1,254,612633,987
?2022
17.
202220211231
123120222021?
564,651217,987?
422,885255,119?
79,04970,065?
63,39845,956
?
38,1241,353?
36,10712,515?
13,696–?
15,21319,591?
5,4603,661
16,0297,7401,254,612633,987202220211231
1231
202220211159,63911,874
183,828114,837(201,650)(67,072)123141,81759,639
?2022
18.
123120222021286,475164,9061162,30244,742
1,640,5081,459,2391025,93822,536123,9761,715
7,0373,821
1,000,890720,551303,162240,71250,35838,810
1,354,4101,000,073
233,8125,9917(218)309
(74,234)(13,528)
44106
202220211231602,585,000463,441,000
?2022
19.
123120222021
(2,003,815)(1,457,816)
1,340,729,5721,206,210,049 (1.49)(1.21)
202220211231
2022202112
?2022
20.2016
20161201620162016265,029,5952016
201120112016
20112022123120112016
5,166,6532016201711
(i)(5)%(ii)
20181129,603,6162016201882016201812201638,553,159
20206201657,200,0002030413201620221231201675,034,504
20162016
201666,300,00020223315%2022622
?2022
20.2018201862018201812,000,000
5635(c)(4)5635(c)(4)20182018
201620188201820162018202262220182018620183,500,000
201882018123,855,3157,355,3156
15%
10%
?2022
20.2018
2022831861,315171.6613.20145.9111.229,6672022228667,160210.5216.19178.9413.769,1832021831425,386308.3023.72262.0620.168,5752021226436,124236.3018.18200.8615.456,7382020831485,069164.0612.62139.4510.735,2032020228425,425145.5411.20123.719.524,048
202212313,666,071
?2022
20.
201120162018
2020123184,991,7155.27 6,244,52426.4612.40 (17,233,853)4.52367,110 (1,797,498)13.272021123172,204,8887.08 12,516,81612.346.40 (5,898,217)4.6352,258 (2,296,634)16.46
2022123176,526,8537.855.33745,340,712
2022123158,017,2195.674.2673,364,735
2022123173,842,9567.605.2734,904,195
?2022
20.
2022123115,825,73788,859,0002.420222021123162,548,00053,571,000
123120222021
5.51~ 9.049.94~ 14.97
1.8% ~ 3.9%1.1% ~ 1.7%
2.82.851% ~ 60%51% ~ 59%
0%0%1010
20222021123120221231
?2022
20.
20162018
2020123134,876,97212.50 17,173,76725.58 (10,703,381)12.23 (5,264,376)15.822021123136,082,98218.33 38,707,66912.46 (12,533,586)16.37 (6,859,892)16.722022123155,397,17314.872022123147,392,28214.87
20221231580,815,000
2.9
202220211231
123120222021139,348114,357163,814126,355303,162240,712
?2022
21.
2020123114,184871(8,113)6,942
13,714(4,504)3099,519(1)
–(67)1,5561,489
13,714(4,571)1,86511,0082021123127,898(3,700)(6,248)17,950
(90,421)(5,311)(446)(96,178)
(1)
––811811
(90,421)(5,311)365(95,367)20221231(62,523)(9,011)(5,883)(77,417)(1)
?2022
22.
202220211231
2019103120191262020924(SPA)20219165,5292,151,87750,000,000202112
192.60391.68115,055,2603,392,616,00023.
10%50%
?2022
23.
202220211231
10%
20221231202112313,548,881,000760,476,00024.
20222021123183,860,00063,772,000401(k)401(k)401(k)
401(k)20214%2022123120211231
401(k)10,298,0007,483,000
?2022
24.
2022202112313,887,0002,986,000
202212312021123145,835,00034,517,00038,075,00026,703,00014
20232,553,000
20221231
20236820245452025442202626020277552028–20327,185
9,255
?2022
25.
20221231117,293,00055,346,00061,947,000BMS
BMS
20221231404,914,000
1,250,000,00020221231595,702,000
2022123122,327,000
19,000,0002022123116,000,000
?2022
25.
(CRO)
26.
383(1)(a)(b)(c)(f)2202220211231
123120222021795724 910828 1,120919 *17,76018,703 1414
19,80420,46420,59921,188
* 2627
?2022
26.
202220211231
(a)
20222021123120221231
Thomas Malley93––391–484
39––210–249Donald W. Glazer74––391–465Michael Goller77––391–468Ranjeev Krishana79––391–470
85––391–476
6––-190–-184Corazon (Corsee) D. Sanders96––391–487Alessandro Riva
71––330–401Margaret Han Dugan
77––330–407697––3,026–3,723
1. 2022622
2. 2022131
3. Alessandro Riva 202221
4. Margaret Han Dugan 202221
?2022
26.(a)
20211231
Thomas Malley89––345–434
76––345–421Donald W. Glazer70––345–415Michael Goller73––345–418Ranjeev Krishana76––345–421
84––345–429
72––396–468Corazon (Corsee) D. Sanders92––339–431
632––2,805–3,437(b)
202220211231
202220211231
123120222021–– 910828 1,120919 14,34315,553 1414
16,38717,314
?
2022
26.(b)
202220211231Anthony C.Hooper202220211231
20221231
100–1503,989–4,239Anthony C. Hooper98––391–489
198–1504,380–4,72820211231
100–1504,704–4,954Anthony C. Hooper92––345–437
192–1505,049–5,391
?2022
27.
202220211231
20222021
123120222021
1,9911,9831,4331,38518,65317,646
373222,11421,046
2022202125,000,00130,000,0001–35,000,00140,000,000–245,000,00150,000,0001–80,000,00185,000,000–1100,000,001105,000,0001–
?2022
27.
202220211231
28.
202220211231
20221231(i)100,0002021100,000(ii)150,0002021150,000(iii)471,9132021241,839
3,000,00020213,000,000(iv)83,499202139,0001,000,000
20211,000,000
14A29.
?2022
29.
123120222021840,032517,173502,626495,26573,263163,8451,415,9211,176,2832022123120221231
112,916,000
?
389,710,00020211231379,607,000
?
115,658,0002022123148,393,00024,870,000
20211231
?2022
30.
20221231
(i)(iii)(iv)(1,640,508)(14,697)–471(1,654,734)(1,277,852)(19,296)–366(1,296,782)
52,480––(3,142)49,338(1,961,037)(33,993)–(2,305)(1,997,335)
(42,778)–10,311–(32,467)(2,003,815)(33,993)10,311(2,305)(2,029,802)
?2022
30.
20211231
(i)(iii)(1,459,239)(21,541)–(1,480,780)
(990,123)(27,189)–(1,017,312)(1,438,588)(48,730)–(1,487,318)
(19,228)5,253(11,775)(25,750)(1,457,816)(43,477)(11,775)(1,513,068)
?2022
30.
20221231
(i)(iii)(ii)(iv)109,960––(2,305)107,6556,379,290––(2,305)6,376,98511,540,97933,993––12,056,915
174,049*307,894*–(7,080,342)(33,993)–(2,305)(7,598,583)
10,311––
(184,360)*(307,894)*–4,383,355––(2,305)4,381,050
?2022
30.
20211231
(i)(ii)(iii)–5,253–110,424125,744
10,067*––8,535,52515,320–110,4248,661,26911,191,00748,730–56,23711,809,005
125,319* 307,894*79,818*(5,076,527)(48,730)–(11,775)(5,568,781)
5,253(307,894)*(13,856)*
(115,252)*––6,132,56315,320–110,4246,258,307
*
?2022
30.
(i)
20221231
33,993,000202148,730,00020215,253,000(ii)
20162307,894,000
307,894,000
?2022
30.
(iii)
20221231
110,424,000
2022123110,311,000(iv)
201911
?2022
30.
(v)
2022123120221231
?2022
31.
123120222021
1,742,3203,715,170 5114 548,3032,044,198 804,471920,819
3,095,1456,680,201 914,65367,434 7,5106,563 6,3287,031 1,621,824543,502
2,550,315624,530
5,645,4607,304,731
446,362292,988 57,316123,341 114,335120,801 297,868247,076
915,881784,206
?2022
31.
123120222021 179,625269,561 166,599118,401
346,224387,9621,262,1051,172,168
0.00019,500,000,000 202220211231 1,356,140,1801,334,804,281135133 11,540,97911,191,007 (77,417)17,950 (7,080,342)(5,076,527)
4,383,3556,132,5635,645,4607,304,731
?2022
31.
202012311,190,821,9411187,414,9326,942(3,618,711)3,803,281
115,055,260123,392,604––3,392,6162,151,877–50,000––50,000 28,778,893392,759––92,762 (2,003,690)–––––
––240,712––240,712–––11,008–11,008––––(1,457,816)(1,457,816)202112311,334,804,28113311,191,00717,950(5,076,527)6,132,563
––(152)––(152)1,375,621––––– 19,960,278246,962––46,964
––303,162––303,162
–––(95,367)–(95,367)
––––(2,003,815)(2,003,815)202212311,356,140,18013511,540,979(77,417)(7,080,342)4,383,355
?2022
32.
2022123120211231
33.
2023329
?2022
202120222021
20223316309301231
306,626341,572387,628380,095(443,287)(439,399)(438,357)(468,622)(435,198)(565,726)(557,556)(445,335)(435,198)(565,726)(557,556)(445,335) (0.33)(0.42)(0.41)(0.33)20213316309301231
605,872149,992206,440213,979
70,167(474,838)(462,325)(571,739)55,580(484,604)(438,114)(590,678)55,580(484,604)(438,114)(590,678) 0.05(0.41)(0.36)(0.48) 0.04(0.41)(0.36)(0.48)
?2022
2011201141520154172011201620161142016
2022429201820182021616
2021912018 2018
20186620188720182022622 ADS
198747
20191031202012
202161620211215
?2022
20101028
2017125
201733BeiGene Switzerland GmbH201791BLA
CMO
CRO
EMA(European Medicines Agency)
?
2022
EUSAEUSA PharmaFDA(U.S. Food and Drug Administration)
(General Data Protection Regulation)(EU)2016/679
19981127
GEM
?2022
NMPA(National Medical Products Administration)
Novartis Pharma AG
201873020221231
sBLA
20191031
?2022
sNDA
?2022
BRAFB-raf BTK
B
cHL
CLL
FcγFcγ
MCL
NSCLC
PARPADPDNA
DNA
PD-11Tpro-B
PD-L1PD-L2PD-1T
?2022
RAFRAFBRAF-BRAF
BRAF-CRAFCRAF-CRAF
SLLTTT
BTIM-3T3Th1
UCWM